Far-infrared therapy improves cardiovascular and infectious outcomes in peritoneal dialysis patients

July 2, 2025

Abstract

Introduction

While far-infrared (FIR) therapy has improved the treatment of various diseases, its effects on peritoneal dialysis (PD) remain understudied. The study aims to investigate the impact of FIR therapy on the cardiovascular and infectious outcomes in PD patients.

Methods

A prospective observational study was conducted for six months, comparing a group receiving FIR therapy (n = 49) with a control group (n = 50). The primary outcome is defined as the composite outcome of three-point major adverse cardiovascular events (3P-MACE), coronary artery disease (CAD), congestive heart failure (CHF), or PD-related infection. The secondary outcomes are: (1) 3P-MACE; (2) 3P-MACE, CAD, or CHF; (3) PD-related infection.

Results

The FIR group consistently exhibited lower incidence rates for primary and secondary outcomes. The primary outcome occurred in six patients (12.2 %) in the FIR group and 15 patients (30 %) in the control group, with incidence rates of 0.26 vs. 0.75 events per patient-year, respectively (p = 0.03). The secondary outcomes for the FIR and control groups were: (1) 3P-MACE occurred in zero patients and four patients (8 %), respectively; (2) composite outcome of 3P-MACE, CAD, or CHF occurred in two patients (4.1 %) and six patients (12 %), respectively; (3) PD-related infection occurred in six patients (12.2 %) and 12 patients (24 %), respectively. Furthermore, FIR therapy significantly reduced hospitalizations for the primary outcome (HR = 0.22; 95 % CI = 0.07–0.71; p = 0.01) and demonstrated better survival rate at six months (85.7 % vs. 67.9 %, respectively). Conclusion: This study suggests that FIR therapy shows promise in reducing hospitalizations associated with cardiovascular and infectious outcomes in PD patients.

-J Formos Med Assoc. 2025 May 26:S0929-6646(25)00239-6

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
FIRAPY collaborates with Taipei Veterans General Hospital in research on non-invasive therapies for

FIRAPY Supports Clinical Research Advancing Non-Invasive Therapies for Peritoneal Dialysis

July 2, 2025
FIRAPY and Taipei Veterans General Hospital co-published a study in JFMA showing improved cardiovascular and infection outcomes in peritoneal dialysis patients using far-infrared therapy.

FIRAPY to Exhibit at 70th JSDT Annual Meeting in Yokohama

June 17, 2025
We are pleased to announce that FIRAPY will be exhibiting at the 70th Annual Meeting of the Japanese Society for Dialysis Therapy (JSDT) , to be held in OSAKA , Japan , from June 27-29, 2025 . 📍 Booth No.: ⑩-96 📅 June 27–29, 2025 📌 Osaka International Convention Center 🔗 Event Website (Japanese) FIRAPY is now adopted by over 200 dialysis facilities across Japan , where it has been used in daily clinical practice to support fistula function maintenance and foot care . With this extensive local experience, FIRAPY has become an important part of non-invasive treatment for Japanese HD patients. We look forward to sharing our latest clinical insights and field experiences at JSDT 2025. If you are attending, we warmly welcome you to stop by Booth ⑩-96 and learn more about how FIRAPY is making a difference in dialysis care. See you in Osaka!
FIRAPY was showcased at ERA 2025 in Vienna, where we reconnected with partners and met new potential

FIRAPY Showcased at ERA 2025 in Vienna

June 8, 2025
FIRAPY Medical was honored to exhibit at ERA 2025 , held at Austria Center Vienna from June 4–7, 2025 . This event marked FIRAPY’s first return to the ERA Congress since the global COVID-19 pandemic , and an important milestone in reconnecting with the European nephrology community. During the congress, our booth (X1.200) attracted considerable attention from both existing partners and new contacts. We were very encouraged by the many productive conversations and the strong interest shown by nephrology professionals across different regions. It was a great pleasure to meet some of our long-standing friends at the event, including: Stanningley Pharma (UK) — our valued distribution partner in the UK for more than 15 years Dr. Dan Heristea (France) — a nephrology expert and friend of FIRAPY Nordic MedCom (Nordic) — a familiar face from past interactions in the industry We were equally pleased to engage with potential new partners from Canada, Morocco, Panama, and the UAE . We look forward to the possibility of building new collaborations to further extend the clinical benefits of FIRAPY to more patients worldwide.  We sincerely thank everyone who visited our booth and supported us throughout the congress. We look forward to continuing these conversations and working together to advance vascular access care and patient outcomes through FIRAPY.
More Posts